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Abstract
Introduction: Adverse drug reactions (ADRs) are under-recognized and under-reported in the Neonatal Intensive Care Unit (NICU)
population, with up to 95% of all ADRs not reported. Compared with non-elderly adults, pediatric patients are 3 times more likely to
experience an ADR, with varying rates from 0.6% to 16.8%. The Children’s Mercy NICU has an ADR rate of 0.29% (2015). This high
rate presents an opportunity to increase recognition and reporting, and improve characterization of ADRs in the NICU. Methods:
The primary aim of this quality improvement project was for 70% of patients who received specified medications (indomethacin, dexmedetomidine, fentanyl, lorazepam, dexamethasone, or hydrocortisone) in the first 3 months of age to be assessed daily for ADRs.
We selected these medications due to the frequency of use and well-understood ADR associations. For each ADR recognized, the
Naranjo score, was calculated and compared with the neonatal-specific Du score to assess the effectiveness of ADR characterization. Results: Implementation occurred on May 15, 2017. We completed 3 PDSA cycles over 1 year. The bedside monitoring tool
was utilized 83% of the time. Twenty-eight potential ADRs were identified, far exceeding the number reported before implementation.
The Du score appeared to better characterize ADRs compared with the Naranjo score. Conclusions: Use of a bedside monitoring
tool improves ADR detection. We experienced challenges with consistently identifying patients on target drugs and getting the tool
to the bedside. Application of the Du score for ADR classification in neonates appears to be more appropriate than the use of the
Naranjo. (Pediatr Qual Saf 2019;4:e203; doi: 10.1097/pq9.0000000000000203; Published online August 30, 2019.)

INTRODUCTION

to neonates. All infants, and preterm infants to a
greater degree have a rapidly evolving physiology with most organs and systems still
undergoing a significant amount of growth
and maturation. Additionally, the disease
states of neonates and infants differ significantly from those of older children and
adults, for whom the majority of medications have been developed and studied.
According to recent literature, ADRs
are under-recognized and under-reported
in the NICU population.3,4 When compared
with non-elderly adults, pediatric patients are at 3
times higher risk to experience an ADR, with neonates
and infants at a still higher risk.3 Incidence rates in children vary from 0.6% to 16.8%.3,5 Even though the risk
is higher in a pediatric patient, there is limited data on
the frequency, morbidity, and mortality from ADRs in pediatric patients, and even less in the NICU population.
ADRs seen in children may differ from adults due to
age-dependent physiological characteristics which may
affect drug pharmacokinetics and pharmacodynamics.
Critically ill neonates and infants are at higher risk due
to the likelihood of organ dysfunction, polypharmacy,
multiple classes of medications, and high medication utilization. The risk of an ADR is exponentially higher in a
patient receiving ≥4 medications.3,5 Of neonates receiving
>10 medications (significant polypharmacy), 30% of
those patients experienced at least 1 ADR.3,5 There is a
lack of understanding of the true incidence of ADRs in

Neonates hospitalized in the Neonatal
Intensive Care Unit (NICU) receive a multitude of medications, many of which are
prescribed off-label.1 These medications
inherently carry the potential for adverse
drug reactions (ADRs), defined by the
World Health Organization as “any noxious or unintended drug response at doses
commonly used for prophylaxis, diagnosis
or treatment of a disease or condition”.2 This
risk is compounded due to several factors unique
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neonates. Based on prior published data, we suspect that
they are grossly underreported.3,5,6
In the NICU at Children’s Mercy Hospital, ADR identification is variable. The Naranjo algorithm,7 a tool developed to identify and characterize ADRs in adult patients,
has been used hospital-wide for the classification of potential ADRs, including in the neonatal population. This
quality improvement process aims to implement the use
of a novel NICU-specific ADR monitoring tool (with
70% of eligible patients showing daily use). In addition
to increasing ADR detection, we will implement the 2012
Du algorithm for ADR classification.8 Based on prior
processes, the Children’s Mercy Hospital NICU has an
ADR rate of 0.29% (3 ADRs out of 1,022 admissions
in 2015). When rates of admission are considered, and
percentages predicted based upon the limited published
data, we should be observing somewhere between 6 and
173 ADRs a year.
The primary aim was for 70% of patients who received
the specified medications in the first 3 months of age to be
assessed daily for ADRs within a 3-month timeframe. After
completion of the first cycle and analysis of the process, we
determined that the process could be improved. The second
Plan-Do-Study-Act (PDSA) cycle focused on increased
pharmacist involvement, and the third on implementation
of an automated identification tool. The secondary aim was
an improvement in our ADR reporting rate by 50% from
the baseline of 3 ADRs per year. The balancing measure was
the classification of ADRs using the neonatal-specific Du
algorithm when compared with the Naranjo algorithm, to
detect any potential discrepancies in reporting.

reviewed the project and determined that it was quality
improvement and not human subject research. Data collection for cycle 1 occurred over 3 months, at which point
results were evaluated to determine the next steps.
The day-to-day process involved the pharmacist for the
team and the bedside nurse primarily. When an order was
placed for one of the above-listed 6 medications, the verifying pharmacist would document some baseline demographic information and a monitoring sheet was taken to
that patient’s bedside. The monitoring sheet arrives at the
bedside either shortly after the drug order if it occurred in
daytime hours or the next day if the drug order occurred
overnight. If the nurse was not familiar with the project, the
pharmacist would explain how to use the sheet to monitor
for potential ADRs. When the bedside nurse identified a
potential ADR, either a pre-suggested reaction or another
non-suggested reaction, the nurse recorded the ADR on
the bedside monitoring sheet. Nursing staff utilized their
routine assessment, lab results, and vital signs to identify
ADRs. They also used the Neonatal Pain, Agitation, and
Sedation Score and relied on baseline patient behavior and
vital sign parameters to assess reactions related to pain or
sedation. The pharmacist would review the bedside sheet
each morning to see if there was a potential ADR in the
last 24 hours. If so, they would collect additional information, score the ADR based on the Naranjo and Du scoring
systems (Fig. 2), and then discuss the potential ADR with
the nurse practitioner and physician for that patient. The
decision to utilize 1 pharmacist was based upon familiarity
with the proposed project and proving that the concept
could work before expanding the initiative. Nurse practitioners and attending neonatologists participated from a
clinical decision standpoint, and it was a goal of the project for each potential ADR to be discussed by the medical
team during rounds. If the team determined that the adverse event was not due to the medication, but rather from
another etiology, they documented this decision on both
the scoring tool and in the medical record.
Evaluation of the process took place after 3 months,
and the subsequent 2 cycles were developed based on
experiences and results. We anticipated that several cycles
would be needed to attain our primary aim. Three cycles
have been completed to date and are discussed within.

METHODS
The Quality Improvement (QI) team consisted of a dedicated NICU pharmacist, a NICU fellow, and an attending
neonatologist. The team discussed and identified barriers
to detecting and discussing ADRs. Among those barriers
identified were the lack of awareness of reporting systems
for ADRs, time limitations during rounds, and difficulty
categorizing adverse reactions as related to a particular
medication. Based on these identified barriers, the team
chose to implement a bedside monitoring process to test
for improvement in ADR detection. Due to personnel limitations, namely a small number of people on the QI team
to implement these processes throughout the large 84-bed
level IV NICU, the team decided to trial the process change
on a selected number of medications that were commonly utilized and had distinctive known and recognizable ADRs, which were familiar to bedside staff. The team
chose 6 high-risk medications to monitor with the project:
indomethacin, dexmedetomidine, fentanyl, lorazepam,
dexamethasone, and hydrocortisone. We developed a bedside paper worksheet to detect and score potential ADRs
(Figs. 1 and 2). For each suspected ADR, we calculated the
Naranjo score and compared it with the score calculated
using the Du algorithm. The institutional review board

RESULTS
The QI project launched on May 15, 2017. After 1 year
and 3 PDSA cycles, we monitored a total of 124 patients
for ADRs. We identified 28 patients with potential ADRs.
The clinical characteristics of these patients are outlined
in Table 1. The median gestation age at birth was 28
weeks, median birth weight was 820 g, and the median
number of medications per patient excluding total parenteral nutrition (TPN)/lipids was 6. Patients were predominantly males and Caucasian.
At the end of the first PDSA cycle, we observed that
1 pharmacist was taking on the brunt of the work with
2
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Fig. 1. Bedside monitoring sheet.

selected medications. We identified 24 potential adverse
reactions. Within this timeframe, there were a total of
1,013 admissions to the NICU, out of whom 124 patients
were monitored. These observed results increase the
overall identification rate of ADRs in our NICU from
0.29% (3/1,022) to 22% (28/124) in the population
monitored. Table 2 is a summary of the adverse reactions
identified according to this process. The increased identification of ADRs based on the 3 PDSA cycles represents a
dramatic increase in the number of ADRs detected, suggesting a much higher rate in the overall NICU population (though not directly quantified in this project) than
what is currently reported. It is important to note that
application of the Du algorithm resulted in a more precise
analysis of each potential adverse reaction.

identifying patients, distributing the bedside tool, collecting the tool, inputting data, and calculating the Du
and Naranjo scores. The overreliance on 1 particular
NICU pharmacist led to variable compliance and analysis at the times that this particular pharmacist was unavailable. This observation highlighted the need to boost
stakeholder engagement. The second cycle focused on
increasing involvement of the entire NICU pharmacy
staff, resulting in a shared workload. The QI team communicated with pharmacists who spent time in the NICU
and devised a workflow that incorporated identification
of patients and distribution of the bedside tool into the
daily tasks of the pharmacists. Data collection occurred
for another 3 months. There continued to be a difficulty
with patient identification, resulting in several target
patients who were missed and did not receive the bedside
tool. The third cycle incorporated the implementation of
an automated Electronic Medical Record (EMR) report
that identified patients on the target medications and then
sent that report to the NICU pharmacy staff twice a day.
The bedside monitoring tool was utilized 83% of the
time for patients who received the noted medications,
accounting for all days the patients were exposed to the

DISCUSSION
We accomplished the primary aim of 70% utilization
of the new bedside tool utilization in the first QI cycle.
Analysis of the data collected suggests that ADRs are
much more prevalent than previously reported and that
there is potential for increased recognition of these events.
3
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Fig. 2. Du and Naranjo ADR scoring tools.

from expected with no intervention needed to rarer serious adverse events requiring either discontinuation of
the medication or additional treatment. These data suggest that there are likely many more unidentified ADRs
present in the NICU because not all patients participated
in the QI project. There is a potential to capture many
more adverse drug events with the implementation of this
tool for all patients and all medications, thus enhancing
the safety of our patients.
One of the challenges in the correct identification of
ADRs in this patient population is the recognition of the
ADR. ADR algorithms have been in use for decades, but do
not always include confounding variables, such as disease
state or concomitant use of other medications. Algorithms
can also vary based on the “weight “of each variable. The
majority of these algorithms, including the Naranjo, have
not been assessed for validity or reliability in neonates and
infants. Du and colleagues published an algorithm in 2012
by that was developed and validated for the neonatal and
infant population.8 This new algorithm was compared with
the existing Naranjo algorithm and was found to be more
reliable for categorizing ADRs in a NICU population. The
Du algorithm can lead to increased specificity in determining
if a potential ADR is truly an ADR in the NICU population.

Table 1. Demographics of Patients with ADRs
Infants with ADRs
Number
GA in weeks*
BW in kg*
No. medications*
No. males†
Race†
Caucasian
African American
Hispanic
Other

28
28 (23–39)
0.82 (0.46–3.89)
6 (3–11)
17 (70%)
16 (57%)
8 (29%)
3 (11%)
1 (3%)

* Median (range).
† Number (percent).

During this project, we noted anecdotally that nurses and
physicians were talking more frequently about ADRs, and
they stopped several medications when an adverse event
was recognized. Raising awareness of potential ADRs
improved the rates of reporting and aided in the correct
identification of each adverse event.
The rate of ADRs detected is significant. Twenty-eight
ADRs out of 124 monitored patients is a rate of 23%. This
ADR rate is more consistent with (and even exceeds) the
published rates of ADRs in children, which ranges from
0.6% to 16.8%.3,5 Importantly, the adverse events ranged
4
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Table 2. Comparison Between Naranjo Score and Du Score for Each Reported ADR
Drug
Dexmedetomidine
Dexamethasone
Indomethacin
Indomethacin
Indomethacin
Dexamethasone
Dexamethasone
Dexmedetomidine
Dexmedetomidine
Dexmedetomidine
Dexmedetomidine
Dexmedetomidine
Dexamethasone
Hydrocortisone
Fentanyl
Hydrocortisone
Dexamethasone
Dexamethasone
Dexamethasone
Hydrocortisone
Hydrocortisone
Dexamethasone
Dexamethasone
Hydrocortisone
Hydrocortisone
Hydrocortisone
Hydrocortisone
Hydrocortisone

ADR
Hypotension
Hypertension
Hypoglycemia
Oliguria
Intestinal perforation
Gastritis
Hypertension
Agitation
Tachycardia
Peripheral edema
Hypotension
Peripheral edema
Agitation
Agitation
Bradycardia
Agitation
Agitation
Tachycardia
Leukocytosis
Hypertension
Hyperglycemia
Hypertension
Agitation
Hypertension
Tachypnea
Hypertension
Agitation
Agitation

Naranjo
Score
3
3
3
2
3
3
3
3
3
2
4
2
3
3
4
4
3
3
3
4
3
5
2
4
3
4
2
3

Du Score
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Possible
Probable
Possible
Possible
Possible
Possible
Possible
Possible

We found that the application of the Du algorithm to
potential ADRs appears to categorize the events in a more
thorough way than previous methods. Based on these
data, the QI team believes that it is possible to systematically screen patients for ADRs and accurately evaluate
them using the Du algorithm. Use of the neonatal specific Du algorithm may lead to increased accuracy when
assessing potential ADRs, allowing the medical team to
make an informed decision regarding the therapeutic
utility of medications.
When designing the QI project, we considered counterbalancing measures, including increased nurse workload,
increased pharmacist workload, and accuracy of ADR
identification utilizing the Du score versus the Naranjo
score. While the process involved did add some additional
work for the bedside nurses, accounting for extra minutes
spent writing down the ADR on the provided bedside
sheet, we believe this is a justified addition given the previously unrecognized prevalence of ADRs and the potential
harm that can come to patients should ADRs go unrecognized and unreported. The pharmacist workload proved to
be significant. Each morning, pharmacists spent about 30
minutes with patients on the selected medications, taking
sheets to the bedside, and entering demographic data into
the monitoring spreadsheet. An additional 15–30 minutes
were dedicated to bedside nursing education, with 15–30
minutes spent collecting bedside sheets and entering ADR
data into the monitoring spreadsheet. The second and third
PDSA cycles specifically addressed this factor, spreading
the workload among all pharmacists in the NICU, and automatically generating a report to identify patients.

9
12
7
7
9
11
14
5
5
3
14
<2
4
6
13
2
4
4
8
26
17
13
8
15
2
9
10
5

Probable
Probable
Probable
Probable
Probable
Probable
Definite
Possible
Possible
Possible
Definite
Unlikely
Possible
Possible
Probable
Unlikely
Possible
Possible
Probable
Definite
Definite
Probable
Probable
Definite
Unlikely
Probable
Probable
Possible

Challenges were present throughout this process, including the occasional loss of bedside tools, limited manpower available to implement this project in an 84-bed
unit, and continued engagement from all physicians. To
combat the waning engagement, we sent periodic email
updates and performed in-person meetings to increase
unit-wide awareness of the project and continue to stimulate engagement. As with any culture shift, it has been
challenging to maintain engagement with the process
among all bedside staff, NNPs, and physicians. The QI
team the safety committee in our NICU will continue to
highlight the importance of considering the impact of
medications on our patients. Maintaining engagement
through the emphasis on the importance of ADR identification and continued education for all clinical personnel
is an ongoing project in the NICU. Development of an
integrated ADR tracking system within the medical record is currently underway. Hopefully, this system will
aid in the visibility of this initiative and engagement of
the medical team. The addition of this ADR-specific EMR
reporting tool will also allow us to expand to more medications and run automated reports of ADR frequency.
The ultimate goal of this QI initiative is to incorporate
detection and discussion of ADRs into the daily workflow
of all clinical personnel and to ingrain pharmacovigilance
into the culture of the Children’s Mercy NICU. As the
project currently stands, the QI team believes it is feasible to expand monitoring of ADRs to include all medications administered to all patients in the NICU, should
additional resources become available. The data from 3
cycles of collection over 1 year showed that incorporating this process into a very small subset of our patients
5
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